Abiopharma

Smith+Nephew PLC Notification

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

FDA approve VORICONAZOLE

FDA approve OMEPRAZOLE MAGNESIUM

FDA approve ASCORBIC ACID

FDA approve GABAPENTIN

FDA approve KETAMINE HYDROCHLORIDE

FDA approve PRUCALOPRIDE SUCCINATE

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

New Form SCHEDULE 13D/A - Prime Medicine, Inc. Filed: 2025-08-11 AccNo: 0001072613-25-000536 Size: 61 KB

New Form 144 - BIOLIFE SOLUTIONS INC Filed: 2025-08-11 AccNo: 0000919574-25-004448 Size: 5 KB